Tumor Necrosis Factor Ligand Superfamily Member 10 / TRAIL (TNFSF10) Antibody (FITC)

Background

TNFSF10, also known as TRAIL (TNF-related apoptosis-inducing ligand), is a cytokine in the tumor necrosis factor (TNF) superfamily, known for its ability to induce apoptosis selectively in cancerous or infected cells. TRAIL is a type II transmembrane protein expressed by various immune cells, such as T cells, NK cells, and macrophages, and plays a pivotal role in immune surveillance and regulation. Unlike other TNF family ligands, TRAIL exhibits the unique ability to preferentially trigger cell death in transformed cells, sparing most normal cells. Its selective cytotoxicity has made it a significant target for cancer therapeutics and an area of research for treatments against viral infections and immune regulation. TRAIL’s role in apoptosis is critical in regulating immune cell function, homeostasis, and tolerance, as it can trigger cell death through both extrinsic and intrinsic pathways. Due to this, TRAIL is an essential component of the immune response to abnormal or damaged cells and has garnered attention as a therapeutic target due to its ability to promote cell death in cancerous or infected cells with minimal toxicity to healthy tissues.